89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g

Trial Profile

89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs MMOT 0530A-Zr-89 (Primary)
  • Indications Adenocarcinoma; Ovarian cancer; Pancreatic cancer
  • Focus Pharmacokinetics
  • Acronyms MMOT
  • Most Recent Events

    • 20 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 22 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 10 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top